EP1972618A1 — Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Assigned to Nabriva Therapeutics AG · Expires 2008-09-24 · 18y expired
What this patent protects
A compound of formula (I) wherein n is 0 to 4; R is ethyl or vinyl; R 1 is hydrogen or (C 1-6 )alkyl, R 2 is hydrogen or - cycloalkyl including (C 3-6 )cycloalkyl, or - unsubstituted (C 1-6 )alkyl, or - (C 1-6 )alkyl substituted by one or more of - hydroxy; prefer…
USPTO Abstract
A compound of formula (I) wherein n is 0 to 4; R is ethyl or vinyl; R 1 is hydrogen or (C 1-6 )alkyl, R 2 is hydrogen or - cycloalkyl including (C 3-6 )cycloalkyl, or - unsubstituted (C 1-6 )alkyl, or - (C 1-6 )alkyl substituted by one or more of - hydroxy; preferably one or two, - halogen, - (C 3-6 )cycloalkyl, or R 1 is hydroxy and R 2 is formyl.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.